Gene therapy play RegenxBio raises $30M

RegenxBio Inc. (Washington, D.C.) raised $30 million in an untranched series C round led by new investors Venrock and Brookside Capital. New investor Deerfield Management, an undisclosed new investor and existing investors FoxKiser and Fidelity Biosciences also participated.

President and CEO Ken Mills told BioCentury the gene therapy platform company plans to use the funds to build the infrastructure that will let the company advance its own programs, rather than simply out-licensing its technology. ...